References
- Cortes J, Thomas D, Rios A et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 94(5), 1492–1499 (2002).
- Mead GM, Sydes MR, Walewski J et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann. Oncol. 13(8), 1264–1274 (2002).
- Magrath IT, Janus C, Edwards BK et al. An effective therapy for both undifferentiated (including Burkitt’s) lymphomas and lymphoblastic lymphomas in children and young adults. Blood 63(5), 1102–1111 (1984).
- Thomas DA, Faderl S, O’Brien S et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106(7), 1569–1580 (2006).
- Magrath I, Lee YJ, Anderson T et al. Prognostic factors in Burkitt’s lymphoma: importance of total tumor burden. Cancer 45(6), 1507–1515 (1980).
- Kian TC, Miriam T, Richard Q et al. Clinical characteristics, prognostic factors and outcomes of Burkitt lymphoma in adult Asians. Leuk. Lymphoma 49(4), 824–827 (2008).
- Wasterlid T, Jonsson B, Hagberg H et al. Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study. Leuk. Lymphoma 52(11), 2090–2096 (2011).
- Castillo JJ, Winer ES, Olszewski AJ. Population-based prognostic factors for survival in patients with Burkitt lymphoma: an analysis from the Surveillance, Epidemiology, and End Results database. Cancer 119(20), 3672–3679 (2013).
- Flowers CR, Fedewa SA, Chen AY et al. Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States. Cancer Epidemiol. Biomarkers Prev. 21(9), 1520–1530 (2012).
- Costa LJ, Xavier AC, Wahlquist AE et al. Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases. Blood 121(24), 4861–4866 (2013).
- Evens AM, Antillon M, Aschebrook-Kilfoy B et al. Racial disparities in Hodgkin’s lymphoma: a comprehensive population-based analysis. Ann. Oncol. 23(8), 2128–2137 (2012).
- Shenoy PJ, Malik N, Nooka A et al. Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer 117(11), 2530–2540 (2011).
- Stiff PJ, Unger JM, Cook J et al. Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). ASCO Meeting Abstracts 29(15 Suppl.), 8001 (2011).
- Bassan R. Toward victory in adult ALL: blinatumomab joins in. Blood 120(26), 5094–5095 (2012).
- Topp MS, Gokbuget N, Zugmaier G et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 120(26), 5185–5187 (2012).
Website
- Surveillance Research [website]. Measures of cancer survival. http://surveillance.cancer.gov/survival/measures.html (Accessed 12 November 2013)